Drug Approval | December 03, 2021
Biocon Pharma receives ANDA approval for Mycophenolic acid
This further adds to Biocon’s portfolio of vertically integrated complex drug products
This further adds to Biocon’s portfolio of vertically integrated complex drug products
Focused medicines company delivering strong operational performance. Building depth in five core therapeutic areas, strength in technology platforms, and a balanced geographic footprint
Market demand for significant volumes and quality of biopharma products would drive continuous manufacturing technologies
The appraisal of the applications has been carried out based on the ranking methodology laid down in the operational guidelines of the Scheme
The multi-target agreement covers five programmes focused on off-the-shelf vaccines for cancer and infectious disease
Fyarro is the first and only approved therapy for adults for the treatment of malignant PEComa in adults
Theradaptive's regenerative implants are best-in-class and are designed to permit precise tissue regeneration for a variety of tissue types and clinical indications
Six-months follow-up of prevention trial showed 83% reduced risk of symptomatic Covid-19, with no severe disease or deaths
Launching in 2022, its availability will be expanded to the global market
It was recognized for its holistic initiatives designed to improve the quality of life and standards of care for patients
Subscribe To Our Newsletter & Stay Updated
